Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

ÖZKURT Z. N., Sucak G. T., Aki S. Z., Yagci M., Haznedar R.

CANCER INVESTIGATION, cilt.35, sa.3, ss.195-201, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 35 Sayı: 3
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1080/07357907.2016.1270958
  • Dergi Adı: CANCER INVESTIGATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.195-201
  • Anahtar Kelimeler: Multiple myeloma, Free light chain, Autologous stem cell transplantation, Prognosis, Progression free survival, NEWLY-DIAGNOSED MYELOMA, HIGH-DOSE MELPHALAN, STANDARD CHEMOTHERAPY, COMPLETE RESPONSE, RANDOMIZED-TRIAL, AUTO-SCT, THERAPY, RATIO, PROGRESSION, SURVIVAL
  • Gazi Üniversitesi Adresli: Evet

Özet

We hypothesized the levels of free light chains obtained before and after autologous stem cell transplantation can be useful in predicting transplantation outcome. We analyzed 70 multiple myeloma patients. Abnormal free light chain ratios before stem cell transplantation were found to be associated early progression, although without any impact on overall survival. At day +30, the normalization of levels of involved free light chain related with early progression. According to these results almost one-third reduction of free light chain levels can predict favorable prognosis after autologous stem cell transplantation.